- Settore: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient in order to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant.
Industry:Pharmaceutical
A vaccine comprise of a canarypox viral vector that carries the gene for human B7. 1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient.
Industry:Pharmaceutical
A vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. The GM-CSF adjuvant stimulates the proliferation of monocytes and monocyte differentiation into macrophages and dendritic cells, immunohematopoietic elements with important antitumoral functions. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.
Industry:Pharmaceutical
A vaccine comprising autologous dendritic cells pulsed with mRNA-encoded Carcinoembryonic Antigen (CEA) that targets tumor cells expressing CEA.
Industry:Pharmaceutical
A vaccine consisting of a plasmid DNA encoding the human melanoma-associated antigen gp100. Upon adminsistration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2. 1-restricted immune response against tumor cells that express this antigen, resulting in tumor cell lysis.
Industry:Pharmaceutical
A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis.
Industry:Pharmaceutical
A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2. 1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis.
Industry:Pharmaceutical
A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis.
Industry:Pharmaceutical
A vaccine consisting of a preparation of allogeneic lymphocytes that encode a gene for telomerase. In transgenic lymphocyte immunization, the transgenic cells are infused into the patient, where they serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase.
Industry:Pharmaceutical
A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis.
Industry:Pharmaceutical
